Graduate Program in Health Sciences, State University of Maringá, Maringá, Paraná, Brazil.
Graduate Program in Bioscience & Physiopathology, State University of Maringá, Maringá, Paraná, Brazil.
Immunotherapy. 2021 Jun;13(8):693-721. doi: 10.2217/imt-2020-0184. Epub 2021 Apr 15.
Current treatments for leishmaniases are not satisfactory, thus alternatives are needed. We searched for clinical trials with immunotherapeutic approaches for patients with leishmaniasis. Out of 205 articles, 24 clinical trials were selected, and eight submitted to meta-analysis. A reduction in healing time was observed in patients with tegumentary leishmaniasis treated with pentavalent antimony plus granulocyte-macrophage colony-stimulating factor, and therapeutic vaccines. Overall meta-analysis indicated that immunotherapy associated with the standard chemotherapy generated a significantly reduced risk of treatment failure than the pentavalent antimony alone (p = 0.03). Our review confirmed the efficacy of immunotherapies for the treatment of cutaneous and visceral leishmaniasis and highlighted the importance of clinical trials using immunotherapies for leishmaniases.
目前针对利什曼病的治疗方法并不令人满意，因此需要寻找替代方法。我们搜索了针对利什曼病患者的免疫治疗方法的临床试验。在 205 篇文章中，选择了 24 项临床试验，其中 8 项进行了荟萃分析。用五价锑加粒细胞-巨噬细胞集落刺激因子和治疗性疫苗治疗皮肤利什曼病患者，可观察到愈合时间缩短。总体荟萃分析表明，与单独使用五价锑相比，免疫疗法联合标准化疗可显著降低治疗失败的风险（p=0.03）。我们的综述证实了免疫疗法治疗皮肤和内脏利什曼病的疗效，并强调了使用免疫疗法治疗利什曼病的临床试验的重要性。
